Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 13, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $49.00 to $18,216,528.97.

Highlighted Stocks Traded by Insiders:

Fastenal (FAST) - FREE Research Report

Heise Rita J., who is Director at Fastenal, bought 3,000 shares at $40.83 on March 13, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was boosted by 150% with the 3,000-share transaction.

The shares most recently traded at $41.28, up $0.45, or 1.1% since the insider transaction. Historical insider transactions for Fastenal go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 60,000
  • 12-Week # shares bought: 1,235
  • 12-Week # shares sold: 60,000
  • 24-Week # shares bought: 1,235
  • 24-Week # shares sold: 60,000

The average volume for Fastenal has been 2.9 million shares per day over the past 30 days. Fastenal has a market cap of $12.1 billion and is part of the services sector and wholesale industry. Shares are down 14.15% year-to-date as of the close of trading on Friday.

Fastenal Company, together with its subsidiaries, engages in the wholesale distribution of industrial and construction supplies in the United States, Canada, and internationally. The company offers fasteners, and other industrial and construction supplies primarily under the Fastenal name. The stock currently has a dividend yield of 2.73%. The company has a P/E ratio of 24.7. Currently, there are 3 analysts who rate Fastenal a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FAST - FREE

TheStreet Quant Ratings rates Fastenal as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Fastenal Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MKS Instruments (MKSI) - FREE Research Report

Anderson Robert R, who is Director at MKS Instruments, sold 500 shares at $34.60 on March 13, 2015. Following this transaction, the Director owned 19,837 shares meaning that the stake was reduced by 2.46% with the 500-share transaction.

The shares most recently traded at $36.03, up $1.43, or 3.97% since the insider transaction. Historical insider transactions for MKS Instruments go as follows:

  • 4-Week # shares bought: 1,161
  • 4-Week # shares sold: 6,325
  • 12-Week # shares bought: 1,161
  • 12-Week # shares sold: 10,096
  • 24-Week # shares bought: 1,161
  • 24-Week # shares sold: 30,136

The average volume for MKS Instruments has been 226,900 shares per day over the past 30 days. MKS Instruments has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are down 3.44% year-to-date as of the close of trading on Friday.

MKS Instruments, Inc. provides instruments, subsystems, and process control solutions that measure, control, power, monitor, and analyze critical parameters of manufacturing processes in the United States and internationally. The stock currently has a dividend yield of 1.89%. The company has a P/E ratio of 16.1. Currently, there are 3 analysts who rate MKS Instruments a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MKSI - FREE

TheStreet Quant Ratings rates MKS Instruments as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full MKS Instruments Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Molina Healthcare (MOH) - FREE Research Report

Barlow Jeff D., who is Chief Legal Officer at Molina Healthcare, sold 5,886 shares at $61.30 on March 13, 2015. Following this transaction, the Chief Legal Officer owned 38,340 shares meaning that the stake was reduced by 13.31% with the 5,886-share transaction.

The shares most recently traded at $63.10, up $1.80, or 2.85% since the insider transaction. Historical insider transactions for Molina Healthcare go as follows:

  • 4-Week # shares sold: 20,895
  • 12-Week # shares sold: 48,427
  • 24-Week # shares sold: 161,511

The average volume for Molina Healthcare has been 697,000 shares per day over the past 30 days. Molina Healthcare has a market cap of $3.1 billion and is part of the health care sector and health services industry. Shares are up 16.31% year-to-date as of the close of trading on Friday.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program. The company operates through two segments, Health Plans and Molina Medicaid Solutions. The company has a P/E ratio of 47.8. Currently, there are 5 analysts who rate Molina Healthcare a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MOH - FREE

TheStreet Quant Ratings rates Molina Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Molina Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null